Xilio Therapeutics reports Q4 2025 results, extends cash runway to 2027

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Xilio Therapeutics reports Q4 2025 results, extends cash runway to 2027
(NASDAQ: XLO) Delayed: 8.31 +0.32 (4.01%)
Previous Close $7.99    52 Week High $ 
Open $8.00    52 Week Low $ 
Day High $8.32    P/E N/A 
Day Low $7.90    EPS $ 
Volume 12,387